POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
A phase I trial of plinabulinin combination with nivolumaband ipilimumabin patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Chemotherapy Induced Profound Neutropenia (PN) in Patients (pts) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim(Peg) Combination versus (vs) Peg Alone. Final Phase 3 Results from PROTECTIVE-2
(BPI-2358-106)
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Clinical Trial Testing Superiority of Combination Plinabulin and Pegfilgrastim vs Pegfilgrastim Alone in Patients with Breast Cancer Treated with High Febrile Neutropenia Risk Chemotherapy: Final Results of the Phase 3 Chemotherapy-Induced Neutropenia Prevention Trial (PROTECTIVE-2)
American Society of Hematology (ASH) Annual Meeting (2020)
12.2020
American Society of Hematology (ASH) Annual Meeting (2020)
PROTECTIVE-2 (BPI-2358-106): A CONFIRMATORY TRIAL TO DEMONSTRATE SUPERIORITY OF THE PLINABULIN + PEGFLIGASTRIM (PLIN/PEG) COMBINATION vs STANDARD OF CARE PEGFILGASTRIM FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NEUTROPENIA (CIN) IN BREAST CANCER PATIENTS
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
12.2021
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
Combination Plinabulin+Pegfilgrastim (Plin+Peg) Had Better Toxicity Management and Health Related Quality-of-Life (HrQoL) Compared to Peg Alone in Early-stage Breast Cancer (BC) Patients (pts) Treated With Taxotere, Doxorubicin and Cyclophosphamide (TAC)
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
12.2021
San Antonio Breast Cancer (SABCS) Annual Symposium 2021
Mechanistic evidence associated with the benefit of plinabulin significantly reducing bone pain in breast cancer patients (pts)
treated with TAC (Docetaxel, Doxorubicin, Cyclophosphamide) and Pegfilgrastim (Peg)
PUBLICATIONS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Cell Reports
09.24.2019
Cell Reports
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-Tumor Responses
Investigational New Drugs
02.16.2011
Investigational New Drugs
Phase 1 Study of the Novel Vascular Disrupting Agent Plinabulin (NPI-2358) and Docetaxel